{"ticker": {"uuid": "9940126f-1f77-49af-9fb8-35fb9864083d", "symbol": "ATRC", "name": "AtriCure Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Medical Instruments & Supplies"}, "articles": [{"title": "Is AtriCure's (ATRC) Russell 2000 Defensive Debut Quietly Reframing Its Risk\u2011Reward Profile?", "summary": "AtriCure (ATRC) has been added to the Russell 2000 Defensive and Growth-Defensive Indexes, potentially broadening its investor base. This inclusion, along with recent executive share purchases, could influence investor perception, though upcoming Q2 2026 earnings are anticipated ", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-atrc/atricure/news/is-atricures-atrc-russell-2000-defensive-debut-quietly-refra/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-07T09:40:38", "published_display": "07 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(ATRC) Movement Within Algorithmic Entry Frameworks", "summary": "This article analyzes Atricure Inc. (NASDAQ: ATRC) using algorithmic entry frameworks. It highlights a strong near and mid-term sentiment but a weak long-term outlook, with an exceptional risk-reward setup. The analysis provides three distinct institutional trading strategies\u2014Pos", "url": "https://news.stocktradersdaily.com/news_release/12/ATRC_Movement_Within_Algorithmic_Entry_Frameworks_070526110802_1783307282.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-06T11:11:49", "published_display": "06 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AtriCure (ATRC) Still Undervalued Following Its Russell Defensive Index Additions?", "summary": "AtriCure (ATRC) has been added to the Russell 2000 Growth-Defensive and Defensive Indices after a recent share price rebound. While analysts peg its fair value at $47.00, suggesting undervaluation based on growth assumptions, a discounted cash flow model presents a more conservat", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-atrc/atricure/news/is-atricure-atrc-still-undervalued-following-its-russell-def", "source_name": "Simply Wall Street", "published_at": "2026-07-05T23:11:17", "published_display": "05 Jul 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of AtriCure, Inc. \u2013 NASDAQ:ATRC", "summary": "The article focuses on the \"Price to sales forward\" metric for AtriCure, Inc. (NASDAQ: ATRC). It appears to be a financial data snippet or a minor report from TradingView, providing a specific valuation metric for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-ATRC/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T00:10:53", "published_display": "04 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure (ATRC) CLO acquires 636 shares in ESPP purchase", "summary": "AtriCure, Inc.'s Chief Legal Officer, Karl S. Dahlquist, acquired 636 shares of common stock through the company\u2019s 2018 Employee Stock Purchase Plan on June 30, 2026. These shares were purchased at $23.78 each, representing 85% of the closing price on that date, increasing his di", "url": "https://www.stocktitan.net/sec-filings/ATRC/form-4-atri-cure-inc-insider-trading-activity-71fcb6730744.html", "source_name": "Stock Titan", "published_at": "2026-07-03T12:09:40", "published_display": "03 Jul 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure to Announce Second Quarter 2026 Financial Results", "summary": "AtriCure, Inc. (NASDAQ: ATRC) announced that it will release its second quarter 2026 financial results on Thursday, July 23, 2026. The company will also host an audio webcast at 4:30 p.m. Eastern Time on the same day to discuss these results. Interested parties can register onlin", "url": "https://finance.yahoo.com/healthcare/articles/atricure-announce-second-quarter-2026-120000941.html", "source_name": "Market source", "published_at": "2026-07-03T11:39:42", "published_display": "03 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure (ATRC) COO adds ESPP shares in routine acquisition", "summary": "AtriCure, Inc. Chief Operating Officer Douglas J. Seith acquired 527 shares of common stock through the company\u2019s 2018 Employee Stock Purchase Plan. The shares were purchased at $23.78 each, reflecting an 85% discount of the closing price on June 30, 2026, and increased his direc", "url": "https://www.stocktitan.net/sec-filings/ATRC/form-4-atri-cure-inc-insider-trading-activity-cfe900bbf5ab.html", "source_name": "Stock Titan", "published_at": "2026-07-03T10:40:26", "published_display": "03 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure (ATRC) CTO adds shares through discounted Employee Stock Purchase Plan", "summary": "AtriCure's Chief Technical Officer, Salvatore Privitera, acquired 636 shares of company stock through the 2018 Employee Stock Purchase Plan (ESPP) on June 30, 2026. These shares were purchased at a discounted price of $23.78 each, representing 85% of the closing price of $27.98 o", "url": "https://www.stocktitan.net/sec-filings/ATRC/form-4-atri-cure-inc-insider-trading-activity-0be315ee6eb3.html", "source_name": "Stock Titan", "published_at": "2026-07-03T10:10:42", "published_display": "03 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: AtriCure to Announce Second Quarter 2026 Financial Results", "summary": "AtriCure, Inc. (Nasdaq: ATRC) announced it will release its second quarter 2026 financial results after the market closes on Tuesday, August 4, 2026. The company will also host a conference call and webcast to discuss the results and provide a business update on the same day at 4", "url": "https://www.moomoo.com/news/post/72398506/press-release-atricure-to-announce-second-quarter-2026-financial-results?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-02T22:39:55", "published_display": "02 Jul 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 AtriCure Inc For: 2 July By Investing.com", "summary": "This article announces the filing of Form 4 for AtriCure Inc. on July 2nd. It provides key stock market data for various indices, commodities, and individual stocks. The content also includes a list of popular news and analysis articles from Investing.com.", "url": "https://ca.investing.com/news/stock-market-news/form-4-atricure-inc-for-2-july-93CH-4718352", "source_name": "Investing.com Canada", "published_at": "2026-07-02T12:40:00", "published_display": "02 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure (ATRC) CEO adds 636 shares through 2018 Employee Stock Purchase Plan", "summary": "AtriCure, Inc.'s President and CEO, Michael H. Carrel, acquired 636 shares of common stock at $23.78 per share through the company's 2018 Employee Stock Purchase Plan. This transaction, executed on June 30, 2026, increased his direct holdings to 779,134 shares. The shares were pu", "url": "https://www.stocktitan.net/sec-filings/ATRC/form-4-atri-cure-inc-insider-trading-activity-04eaee686c77.html", "source_name": "Stock Titan", "published_at": "2026-07-02T12:40:00", "published_display": "02 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure, Inc. (ATRC) CSO acquires 636 ESPP shares at discount", "summary": "AtriCure, Inc.'s Chief Scientific Officer, Doraiswamy Vinayak, acquired 636 shares of common stock through the company's 2018 Employee Stock Purchase Plan. The shares were purchased on June 30, 2026, at a discounted price of $23.78 per share, which is 85% of the closing price of ", "url": "https://www.stocktitan.net/sec-filings/ATRC/form-4-atri-cure-inc-insider-trading-activity-ecf8370c72d9.html", "source_name": "Stock Titan", "published_at": "2026-07-02T12:40:00", "published_display": "02 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canaccord reiterates AtriCure stock Buy rating after FDA clearance", "summary": "Canaccord Genuity has reiterated its Buy rating and a $55.00 price target for AtriCure Inc. (NASDAQ:ATRC) following FDA clearance for a competing left atrial appendage exclusion system from Edwards Lifesciences. Despite the new competition, Canaccord expects minimal impact on Atr", "url": "https://www.investing.com/news/analyst-ratings/canaccord-reiterates-atricure-stock-buy-rating-after-fda-clearance-93CH-4767601", "source_name": "Investing.com", "published_at": "2026-06-30T22:09:46", "published_display": "30 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure | 4: Statement of changes in beneficial ownership of securities-Officer Privitera Salvatore", "summary": "This document from AtriCure reports a Statement of Changes in Beneficial Ownership of Securities (Form 4) for Officer Privitera Salvatore. It details alterations in his holdings of company securities as required by regulatory guidelines.", "url": "https://www.moomoo.com/news/notice/307655653/atricure-4-statement-of-changes-in-beneficial-ownership-of-securities", "source_name": "Moomoo", "published_at": "2026-06-30T13:42:41", "published_display": "30 Jun 2026 13:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canaccord reiterates AtriCure stock Buy rating after FDA clearance By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQcDFEUFk2MUFRQmxnNWlqcUkxUnZlMjBteWpTU1NSdHV1QWM1RV9UWmF3MFVDWEtBamJaNTZoazBOb200RGRacDZnMVI0aUpRWXJLOE1oRHUzTl9PUng1d1k3elE2OUJiTm1wUVF4WEs5bWdmZXRpdk1Oamptakd0SUZWYnAzc0VjcHpWbnJMcDgwbWRoSXFyVnNQT1Jjc2tMaExMaEpOaVBBLVhwSnZXalQzOExnd1R0TnNXbHc2eTlJaFdLZHc?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-06-30T11:57:51+00:00", "published_display": "30 Jun 2026 11:57", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure (ATRC) Joins Multiple Russell 2000 Defensive Indexes Is Its Risk Profile Evolving?", "summary": "AtriCure (ATRC) has been added to the Russell 2000 Growth-Defensive and Defensive indexes, which could boost its visibility and liquidity. While this inclusion may attract investment, the fundamental risks and opportunities related to its product pipeline and competition, particu", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-atrc/atricure/news/atricure-atrc-joins-multiple-russell-2000-defensive-indexes", "source_name": "Simply Wall Street", "published_at": "2026-06-29T20:14:26", "published_display": "29 Jun 2026 20:14", "sentiment": "positive", "sentiment_pct": 63, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edwards wins FDA clearance for LAA clip, setting up competition with AtriCure and Medtronic", "summary": "Edwards Lifesciences has received FDA clearance for its Ecliptis left atrial appendage exclusion system, positioning it to compete with AtriCure's AtriClip and Medtronic's Penditure system. The device aims to prevent stroke in atrial fibrillation patients by closing the LAA. Edwa", "url": "https://finance.yahoo.com/healthcare/articles/edwards-wins-fda-clearance-laa-111638931.html", "source_name": "Market source", "published_at": "2026-06-29T11:39:26", "published_display": "29 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure, Inc.(NasdaqGM: ATRC) added to Russell 2000 Defensive Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPa09TenVFMndXZXFYaklwMFJERjhSb0lKc1Zhc2hOY1FYY3dWNmd2NXNhV2NUNzllMzJralcxTURyRFVFZW5VMk04U0hZbzY2bElwcGExVXU3U0diMnBIYTMwN2tJUU5ua1pOWTJyU01JaDh5RmY4THR5THl2aDY0b2RQajhsWkx3YWNQbVY3WVotbXpDNEFLc0kzOThMWU90ejVWM2FYVDFweXZHYXBlNG5KQ3IxMWRi?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure, Inc. Actuals & Estimates (NASDAQ:ATRC)", "summary": "This article provides an overview of AtriCure, Inc. (NASDAQ: ATRC) stock, including its current price of $30.18, market capitalization of $1.42 billion, and recent performance. It details analyst forecasts, with a maximum estimate of $55.00 and a minimum of $36.00, and mentions k", "url": "https://www.tradingview.com/symbols/NASDAQ-ATRC/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T21:09:31", "published_display": "26 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATRC Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides an overview of AtriCure, Inc. (ATRC) stock, including its current price, analyst forecasts, and historical performance. It details financial metrics such as revenue, net income, and market capitalization, along with upcoming earnings dates. The content also a", "url": "https://www.tradingview.com/symbols/NASDAQ-ATRC/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T09:40:49", "published_display": "26 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure, Inc. Actuals & Estimates (DUS:A5I)", "summary": "This article provides financial actuals and estimates for AtriCure, Inc. (DUS:A5I), including its stock ticker, analyst forecast, historical prices, revenue, net income, and EBITDA. It also notes that the company does not pay dividends and details its next earnings report date.", "url": "https://www.tradingview.com/symbols/DUS-A5I/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-06-26T03:40:43", "published_display": "26 Jun 2026 03:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure stock trades up with limited momentum as technical resistance remains", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOSHBUR1g1bTdsYTdqS3pXZ1M4cmJDSDJiVms0X2l0TmJMX19pM0NzdlRtOVZGcWJDZTJPVUljMEI5RGtTRU1yYUY4a1BscGlUdnc0Y1l5djRDbDVZRmNTVkFkM1g2eGtvSjZGbkUyVVhuOGFSZWhOOFJhMHVQTWQ2WGx5WjVhOVM4T3JqVmRMc0tpOHM?oc=5", "source_name": "Traders Union", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure Inc (ATRC) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for AtriCure Inc (ATRC), detailing its volatility, financial risk, and investment risk. The company has a risk assessment score of 6.67, ranking 52 out of 204 in the Healthcare Equipment & Supplies industry, and a beta of 1.27, indicating h", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atrc/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-24T02:41:17", "published_display": "24 Jun 2026 02:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure (ATRC) Stock Could Be 45.4% Undervalued As Growth Narrative Faces A Cash Flow Test", "summary": "AtriCure (ATRC) stock is currently trading around $28.80, with one narrative suggesting it is 45.4% undervalued with a fair value of $52.78, based on strong growth assumptions from its innovative medical devices. However, a discounted cash flow (DCF) model presents a contrasting ", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-atrc/atricure/news/atricure-atrc-stock-could-be-454-undervalued-as-growth-narra", "source_name": "Simply Wall Street", "published_at": "2026-06-21T18:09:26", "published_display": "21 Jun 2026 18:09", "sentiment": "negative", "sentiment_pct": 28, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure (ATRC) Soars 6.2%: Is Further Upside Left in the Stock?", "summary": "AtriCure (ATRC) shares rose 6.2% after a presentation at the Goldman Sachs Global Healthcare Conference, where management reiterated a goal of $1 billion in revenue by 2030 and highlighted market expansion potential from clinical trials. Despite the surge, the stock holds a Zacks", "url": "https://finance.yahoo.com/markets/stocks/articles/atricure-atrc-soars-6-2-113600767.html", "source_name": "Market source", "published_at": "2026-06-19T11:40:46", "published_display": "19 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 68, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure Inc (ATRC) Financial Health: Profitability & Balance Sheet Analysis", "summary": "AtriCure Inc (ATRC) currently holds a robust financial score of 7.37, ranking 81st in the Healthcare Equipment & Supplies industry. The company reported a significant quarterly revenue increase of 14.26% year-over-year, reaching $141.25 million, and a net profit increase of 101.6", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atrc/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T16:10:38", "published_display": "18 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure Inc (ATRC) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of AtriCure Inc (ATRC), detailing its current price momentum score, support and resistance levels, and indicator readings. It shows that ATRC is trading between a resistance level of $30.29 and a support level of $26.34, suggesting poten", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atrc/technical", "source_name": "TradingKey", "published_at": "2026-06-18T07:44:51", "published_display": "18 Jun 2026 07:44", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure Inc (ATRC) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for AtriCure Inc (ATRC), detailing its current earnings forecast score, average price target, and analyst ratings. Based on 10 analysts, the stock has a \"Buy\" trend with an average target price of $50.00 and an expected revenue of $152.0", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atrc/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T06:38:59", "published_display": "18 Jun 2026 06:38", "sentiment": "positive", "sentiment_pct": 81, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure Inc (ATRC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTFBMZUtaQ3A1YkFFRjVQMUpzZl9BU2RjdUJGdE9pQUpacXg1VVBNQnBzcGk2aS1seXhBb1hpX2RyWWJ5WFZXYWlkd3lJanBheUROdnNGX3JhOVdackJiUVlTOEJQMjQwRWQ4Zl9HZ2t3?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T21:00:31+00:00", "published_display": "17 Jun 2026 21:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure Inc (ATRC) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure and institutional holdings of AtriCure Inc (ATRC). It lists the major shareholders, their proportion of holdings, and categorizes shareholders by type. The report also provides a historical overview of institutional shareholding data", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atrc/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T21:10:11", "published_display": "17 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure (ATRC) Declines 2.8% as Shares Approach Critical Support at $26.58 - Sweep Order Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOYXA5S2Y4a2lsdTVaNDd6Zml3eUFpcEp5TXVRMTJrZnhKOXV3NzdJNE5QVUVqQVFRNFZEZXJoSHlYdDBCWHZNVzZXUjBoR1E3dW54WnY1Yk52WGRqRnA1X3FxY1pUekMyeHQxUGkyUnZrQXlncF9ETEFCSUdNOS1LcUVDQWdHVGJMZTYzRF9yNElMYmJwLWY5V2k5NTdvaXhha090VVZjUnZZLXBYYlN4QklvVXlnVzFzWkE?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Do Options Traders Know Something About AtriCure Stock We Don't?", "summary": "", "url": "https://finance.yahoo.com/markets/options/articles/options-traders-know-something-atricure-134300217.html", "source_name": "Zacks", "published_at": "2026-06-11T13:43:00+00:00", "published_display": "11 Jun 2026 13:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At AtriCure (ATRC) Valuation As BoxX NoAF Trial Acceleration Draws Investor Attention", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNSjNOUFdKWlV0b0M4N21IY0FYaS1yM2dEa2pIYVBuZ2tON3YtbkRMRVBySHNfOERyazBNZGtSMm4teFlBTlpjbWV0VFprTkVZTEQ4ODNOcE1uemNtYVNaU2dPMHVOc0FfcHdXYTJuVTlqdGhnckFVakgyZXRNbk1faWdHQmd6MktoajVTclNQMlpCWkZnYWJtbG1KRzJJT3M?oc=5", "source_name": "Market source", "published_at": "2026-06-06T07:00:00+00:00", "published_display": "06 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure (ATRC) Advances Key Heart Disease Trial 12 Months Ahead of Schedule", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/atricure-atrc-advances-key-heart-214556164.html", "source_name": "Insider Monkey", "published_at": "2026-06-04T21:45:56+00:00", "published_display": "04 Jun 2026 21:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook", "summary": "", "url": "https://finance.yahoo.com/m/b304e545-2f29-370c-8775-b28720e2612f/atricure-conference%3A-new.html", "source_name": "MarketBeat", "published_at": "2026-05-12T19:10:19+00:00", "published_display": "12 May 2026 19:10", "sentiment": "positive", "sentiment_pct": 58, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing AtriCure (ATRC) Valuation After A Prolonged Share Price Decline", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOVHFXRnl3Um1oTjB0Wm9jMWJ6cXV6eDVIRkNTaXhxQ1hyNnZ4YkJPQW1HeTRDOU1zWmJtWXBDOUthdy16RkpSSmNFN3YwYjduWjlJejJvTXVydkxSTlJoMU15X0x6eDFaZWVrOWpPWXNNZ3BMMzF2VXRxYW42NDhXNVlTNld3OHJWWXl5Q0RybUZKdzhJUkVhZFRuVkVmWFUyVDlWRUxraWtleURL?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure (ATRC) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/6159115b-382e-3b04-a527-56479a1fec92/atricure-%28atrc%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-05-06T14:30:28+00:00", "published_display": "06 May 2026 14:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure (ATRC) Reports Break-Even Earnings for Q1", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNSUtQa2lIZFRTRi1mTkxhcXROY0N0d0RlSUF2V1REcjRjcEZRM2NPRzFzeFN1VmRsWVJzX3dHejNKZUVrS0paT3ZxQmh6REx4S0dLZUxUbGNtZlhyWUFDVHNZWXV4T1YtSk92a1ZkeGhMd2c4TVBaM01OWkN6M0NaWFpiaEFEMURIczVpOHl5SElnVW1HN2xwOHBrSGpZRWJhOTlV?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atricure stock hits 52-week low at $27.30 amid market challenges", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQalhmcDF1MnJTVmhpcHlvakxIZG5kZV8tNzRHWC1fMkJTNm5sOG5PQWlYeDA3ekFPZWEzNXlFZ1k1akxZcFBKU2JDYXpsc1g4c19EMmtqSngtNjRjaFk5c0k3OEZUSVZWN0JWb01ZYXpMNlFDN2ZoN2gyRjRZNUk0c3N5RENXUVUwX1JLVnhhdWF1ejk4YUFHMUwxWHY5MXg1TnJQX3B3U3dWZ0U3RjZIeDBBb05xODZyVnc?oc=5", "source_name": "Investing.com", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing AtriCure (ATRC) Valuation After Prolonged Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNU1hDcmR2MkRZYkhnZGV6cy1OMmlnUWo1alhfRFRZWjN2ZmhnRG5na0tyRy04NGo4MVJlbjNFVGV0N2JJZUt3RnEzcWNGVEE2NmpxbEdJRzk1RW5JSWlPSnNVNTdtZUFjYXBPVEFiSzliUEZfbEowZEY2Si1BZ090NkVMS2RIR3NJTkJJQ28tcWliNTVrOS1aaXYyT3p2eXZKTXZGVVVrbWE4NEc0?oc=5", "source_name": "Market source", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure, Inc. ($ATRC) CEO 2025 Pay Revealed", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxOcUFFZ0s1VldIU2FyZ05MZDhFbkJpZEZYdkN3SThTVjkwTzcyR1lPaTBsa1d0T0NLaE90NlNyWTZQYklOMXQ0LTFrYmFzOHhteFRpR2s2enZWRlBKRWxZdFNqdG5teUswRmZUUmVzdFg3dlVxZ21UZzRUelRVcGZaOU50MA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure CSO Sells 5,000 Shares \u2014 A Modest Trim or a Pattern Worth Watching?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxObW5UcTZWOEZSRklwT0M0cWNCNFBGcUJLdUFTbnBkbDRIWVpRRU1fcmlCa1JMU21PTE5LbjhXNWVrVk9VdjdYZFQ0bmJ1c1dvZGotMXpDRWxTanJSa2ZuVFl6eXc2ZDYzSTFJSHdjNVppSTVoUFFYUENnNVFQdDRVbDI0NXhMM3dmMG5PSXkxQ0EwNk9SOTVTWUhrSHppV3NKZWRBQ2swdWVpbGkzLUZUTFhVOFZkd1lHZ0tPUHpzNW0?oc=5", "source_name": "The Motley Fool", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure Inc (ATRC) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE5aY3JsZm1HRE5xNk9xYkNJNFkwWXBkakJSc2duM0JiNDFCejFTRGJGSXBPR3RqZFg2Y1oxTjh4a21admNyTll0MTdzRGpwb25TTGtMc1NkZw?oc=5", "source_name": "Gotrade", "published_at": "2026-02-05T19:34:30+00:00", "published_display": "05 Feb 2026 19:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AtriCure Stock a Buy or Sell After a Director Dumped 10,000 Shares?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPdDAwOUJfbFNNY2RWVmpOUlpDZ2Ywd21FR1BFTF9BN2xpRlZhU05aQ0hwRDdTSWdwRk5GUS1ydDhNMTdjbmwxV3FJMUtBN2gtdUhvSTNfV2VyQVJKWDNZYUpDeUhTZmxaeEYtbzRKNG9EazRCMHRZTDFYX1VCSlBxNXZkVlFDaElEbUpMcHNwTXVqY0ZmbWl5d1JJS1oydFpMZi03RVNwejZDR1ZmdV91UWNPd0IxdktaalE4?oc=5", "source_name": "The Motley Fool", "published_at": "2025-11-29T08:00:00+00:00", "published_display": "29 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Numerous AtriCure Insiders Sold Stock: Not A Positive Omen", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-30T07:00:00+00:00", "published_display": "30 Jul 2025 07:00", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure (NASDAQ:ATRC) Has Debt But No Earnings; Should You Worry?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-08T07:00:00+00:00", "published_display": "08 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unveiling AtriCure (ATRC)'s Value: Is It Really Priced Right? A Comprehensive Guide", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxNQ0xEeWFBaXRmeHBETjNIUi15ZUNjT3R3a25XN0hjNWZhNGpMNF9TcDV1ZWdzaFYtR3JSVmg5UVpWVmhlNzJvSExHM2kwUnVJVUJoYmxGUkZWTDg0VHF0T1JscjVsVncxTGUyQXFINWFlREJZWklWSFJNOW5qTTJESnhtNnBkTXZlaGVBS1FCZTl5OWV1ZjJoRmVoa3BmMEU1YVJndm9Fclg2WUg4ZlpWRFdWU0VyZHNNNzY4SzZ2S1hrRmE4S2x0YV8wX3RoUUhDQ3FLSEYwVmx5enN0cVE?oc=5", "source_name": "GuruFocus", "published_at": "2023-11-28T08:00:00+00:00", "published_display": "28 Nov 2023 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure agrees to buy LARIAT developer SentreHEART -", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQelhiaXJpNWJtSDJVZE1UWExBM0ZyU0hBRlhleXAxSUZoRE55ZnhhYVVBSTZsS0RteFJHX1pkcGV0NG03NlVFRHJBdXlkWGczTS1fYlViVWN0REhkdHJHYnduZTh2YndZNE9ZbTNVZ0laVzJoZlJ6WVQ0Ymo4QS04QmFtemxWeHBTcmc?oc=5", "source_name": "Cardiac Rhythm News", "published_at": "2019-09-16T07:00:00+00:00", "published_display": "16 Sep 2019 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure enters into definitive agreement to acquire SentreHeart", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOMnZ0cEQ5XzJWY1pPc0tkM2VHTDd3YXhpenJ3X0xIc2Y1QnpkOUhUb3FBdWI1UmRjX0lrWDFrZ2hITEZkVE05N2pldm52MG1faU9uYWlIaVFBaUlCSDdfdmF0dWNkYXVMa28yOUx0VHF0WXZJM3JHVDVTc2VqMC1TRFU2amE4U0xWNWowVGJUc2JhVmpTcHZNSUd3NA?oc=5", "source_name": "Cardiac Rhythm News", "published_at": "2019-08-15T07:00:00+00:00", "published_display": "15 Aug 2019 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATRC Stock Price and Chart \u2014 NASDAQ:ATRC", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE4zeVd1SWE3ZU5xaXN3VVlha0IwZzhic3FKOHpQYlhTQmNJcllGMTZGZkJDUW9PVmJmY2hLeFR6Sm5TRGxjb2N4NlVVUzZpM2txQ1YzM0FLNDcxR0JF?oc=5", "source_name": "TradingView", "published_at": "2017-07-21T02:31:46+00:00", "published_display": "21 Jul 2017 02:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Is AtriCure's (ATRC) Russell 2000 Defensive Debut Quietly Reframing Its Risk\u2011Reward Profile?", "summary": "AtriCure (ATRC) has been added to the Russell 2000 Defensive and Growth-Defensive Indexes, potentially broadening its investor base. This inclusion, along with recent executive share purchases, could influence investor perception, though upcoming Q2 2026 earnings are anticipated ", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-atrc/atricure/news/is-atricures-atrc-russell-2000-defensive-debut-quietly-refra/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-07T09:40:38", "published_display": "07 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(ATRC) Movement Within Algorithmic Entry Frameworks", "summary": "This article analyzes Atricure Inc. (NASDAQ: ATRC) using algorithmic entry frameworks. It highlights a strong near and mid-term sentiment but a weak long-term outlook, with an exceptional risk-reward setup. The analysis provides three distinct institutional trading strategies\u2014Pos", "url": "https://news.stocktradersdaily.com/news_release/12/ATRC_Movement_Within_Algorithmic_Entry_Frameworks_070526110802_1783307282.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-06T11:11:49", "published_display": "06 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AtriCure (ATRC) Still Undervalued Following Its Russell Defensive Index Additions?", "summary": "AtriCure (ATRC) has been added to the Russell 2000 Growth-Defensive and Defensive Indices after a recent share price rebound. While analysts peg its fair value at $47.00, suggesting undervaluation based on growth assumptions, a discounted cash flow model presents a more conservat", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-atrc/atricure/news/is-atricure-atrc-still-undervalued-following-its-russell-def", "source_name": "Simply Wall Street", "published_at": "2026-07-05T23:11:17", "published_display": "05 Jul 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of AtriCure, Inc. \u2013 NASDAQ:ATRC", "summary": "The article focuses on the \"Price to sales forward\" metric for AtriCure, Inc. (NASDAQ: ATRC). It appears to be a financial data snippet or a minor report from TradingView, providing a specific valuation metric for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-ATRC/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T00:10:53", "published_display": "04 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure (ATRC) CLO acquires 636 shares in ESPP purchase", "summary": "AtriCure, Inc.'s Chief Legal Officer, Karl S. Dahlquist, acquired 636 shares of common stock through the company\u2019s 2018 Employee Stock Purchase Plan on June 30, 2026. These shares were purchased at $23.78 each, representing 85% of the closing price on that date, increasing his di", "url": "https://www.stocktitan.net/sec-filings/ATRC/form-4-atri-cure-inc-insider-trading-activity-71fcb6730744.html", "source_name": "Stock Titan", "published_at": "2026-07-03T12:09:40", "published_display": "03 Jul 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure to Announce Second Quarter 2026 Financial Results", "summary": "AtriCure, Inc. (NASDAQ: ATRC) announced that it will release its second quarter 2026 financial results on Thursday, July 23, 2026. The company will also host an audio webcast at 4:30 p.m. Eastern Time on the same day to discuss these results. Interested parties can register onlin", "url": "https://finance.yahoo.com/healthcare/articles/atricure-announce-second-quarter-2026-120000941.html", "source_name": "Market source", "published_at": "2026-07-03T11:39:42", "published_display": "03 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure (ATRC) COO adds ESPP shares in routine acquisition", "summary": "AtriCure, Inc. Chief Operating Officer Douglas J. Seith acquired 527 shares of common stock through the company\u2019s 2018 Employee Stock Purchase Plan. The shares were purchased at $23.78 each, reflecting an 85% discount of the closing price on June 30, 2026, and increased his direc", "url": "https://www.stocktitan.net/sec-filings/ATRC/form-4-atri-cure-inc-insider-trading-activity-cfe900bbf5ab.html", "source_name": "Stock Titan", "published_at": "2026-07-03T10:40:26", "published_display": "03 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure (ATRC) CTO adds shares through discounted Employee Stock Purchase Plan", "summary": "AtriCure's Chief Technical Officer, Salvatore Privitera, acquired 636 shares of company stock through the 2018 Employee Stock Purchase Plan (ESPP) on June 30, 2026. These shares were purchased at a discounted price of $23.78 each, representing 85% of the closing price of $27.98 o", "url": "https://www.stocktitan.net/sec-filings/ATRC/form-4-atri-cure-inc-insider-trading-activity-0be315ee6eb3.html", "source_name": "Stock Titan", "published_at": "2026-07-03T10:10:42", "published_display": "03 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: AtriCure to Announce Second Quarter 2026 Financial Results", "summary": "AtriCure, Inc. (Nasdaq: ATRC) announced it will release its second quarter 2026 financial results after the market closes on Tuesday, August 4, 2026. The company will also host a conference call and webcast to discuss the results and provide a business update on the same day at 4", "url": "https://www.moomoo.com/news/post/72398506/press-release-atricure-to-announce-second-quarter-2026-financial-results?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-02T22:39:55", "published_display": "02 Jul 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 AtriCure Inc For: 2 July By Investing.com", "summary": "This article announces the filing of Form 4 for AtriCure Inc. on July 2nd. It provides key stock market data for various indices, commodities, and individual stocks. The content also includes a list of popular news and analysis articles from Investing.com.", "url": "https://ca.investing.com/news/stock-market-news/form-4-atricure-inc-for-2-july-93CH-4718352", "source_name": "Investing.com Canada", "published_at": "2026-07-02T12:40:00", "published_display": "02 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure (ATRC) CEO adds 636 shares through 2018 Employee Stock Purchase Plan", "summary": "AtriCure, Inc.'s President and CEO, Michael H. Carrel, acquired 636 shares of common stock at $23.78 per share through the company's 2018 Employee Stock Purchase Plan. This transaction, executed on June 30, 2026, increased his direct holdings to 779,134 shares. The shares were pu", "url": "https://www.stocktitan.net/sec-filings/ATRC/form-4-atri-cure-inc-insider-trading-activity-04eaee686c77.html", "source_name": "Stock Titan", "published_at": "2026-07-02T12:40:00", "published_display": "02 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure, Inc. (ATRC) CSO acquires 636 ESPP shares at discount", "summary": "AtriCure, Inc.'s Chief Scientific Officer, Doraiswamy Vinayak, acquired 636 shares of common stock through the company's 2018 Employee Stock Purchase Plan. The shares were purchased on June 30, 2026, at a discounted price of $23.78 per share, which is 85% of the closing price of ", "url": "https://www.stocktitan.net/sec-filings/ATRC/form-4-atri-cure-inc-insider-trading-activity-ecf8370c72d9.html", "source_name": "Stock Titan", "published_at": "2026-07-02T12:40:00", "published_display": "02 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canaccord reiterates AtriCure stock Buy rating after FDA clearance", "summary": "Canaccord Genuity has reiterated its Buy rating and a $55.00 price target for AtriCure Inc. (NASDAQ:ATRC) following FDA clearance for a competing left atrial appendage exclusion system from Edwards Lifesciences. Despite the new competition, Canaccord expects minimal impact on Atr", "url": "https://www.investing.com/news/analyst-ratings/canaccord-reiterates-atricure-stock-buy-rating-after-fda-clearance-93CH-4767601", "source_name": "Investing.com", "published_at": "2026-06-30T22:09:46", "published_display": "30 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure | 4: Statement of changes in beneficial ownership of securities-Officer Privitera Salvatore", "summary": "This document from AtriCure reports a Statement of Changes in Beneficial Ownership of Securities (Form 4) for Officer Privitera Salvatore. It details alterations in his holdings of company securities as required by regulatory guidelines.", "url": "https://www.moomoo.com/news/notice/307655653/atricure-4-statement-of-changes-in-beneficial-ownership-of-securities", "source_name": "Moomoo", "published_at": "2026-06-30T13:42:41", "published_display": "30 Jun 2026 13:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canaccord reiterates AtriCure stock Buy rating after FDA clearance By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQcDFEUFk2MUFRQmxnNWlqcUkxUnZlMjBteWpTU1NSdHV1QWM1RV9UWmF3MFVDWEtBamJaNTZoazBOb200RGRacDZnMVI0aUpRWXJLOE1oRHUzTl9PUng1d1k3elE2OUJiTm1wUVF4WEs5bWdmZXRpdk1Oamptakd0SUZWYnAzc0VjcHpWbnJMcDgwbWRoSXFyVnNQT1Jjc2tMaExMaEpOaVBBLVhwSnZXalQzOExnd1R0TnNXbHc2eTlJaFdLZHc?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-06-30T11:57:51+00:00", "published_display": "30 Jun 2026 11:57", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure (ATRC) Joins Multiple Russell 2000 Defensive Indexes Is Its Risk Profile Evolving?", "summary": "AtriCure (ATRC) has been added to the Russell 2000 Growth-Defensive and Defensive indexes, which could boost its visibility and liquidity. While this inclusion may attract investment, the fundamental risks and opportunities related to its product pipeline and competition, particu", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-atrc/atricure/news/atricure-atrc-joins-multiple-russell-2000-defensive-indexes", "source_name": "Simply Wall Street", "published_at": "2026-06-29T20:14:26", "published_display": "29 Jun 2026 20:14", "sentiment": "positive", "sentiment_pct": 63, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edwards wins FDA clearance for LAA clip, setting up competition with AtriCure and Medtronic", "summary": "Edwards Lifesciences has received FDA clearance for its Ecliptis left atrial appendage exclusion system, positioning it to compete with AtriCure's AtriClip and Medtronic's Penditure system. The device aims to prevent stroke in atrial fibrillation patients by closing the LAA. Edwa", "url": "https://finance.yahoo.com/healthcare/articles/edwards-wins-fda-clearance-laa-111638931.html", "source_name": "Market source", "published_at": "2026-06-29T11:39:26", "published_display": "29 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure, Inc.(NasdaqGM: ATRC) added to Russell 2000 Defensive Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPa09TenVFMndXZXFYaklwMFJERjhSb0lKc1Zhc2hOY1FYY3dWNmd2NXNhV2NUNzllMzJralcxTURyRFVFZW5VMk04U0hZbzY2bElwcGExVXU3U0diMnBIYTMwN2tJUU5ua1pOWTJyU01JaDh5RmY4THR5THl2aDY0b2RQajhsWkx3YWNQbVY3WVotbXpDNEFLc0kzOThMWU90ejVWM2FYVDFweXZHYXBlNG5KQ3IxMWRi?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure, Inc. Actuals & Estimates (NASDAQ:ATRC)", "summary": "This article provides an overview of AtriCure, Inc. (NASDAQ: ATRC) stock, including its current price of $30.18, market capitalization of $1.42 billion, and recent performance. It details analyst forecasts, with a maximum estimate of $55.00 and a minimum of $36.00, and mentions k", "url": "https://www.tradingview.com/symbols/NASDAQ-ATRC/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T21:09:31", "published_display": "26 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATRC Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides an overview of AtriCure, Inc. (ATRC) stock, including its current price, analyst forecasts, and historical performance. It details financial metrics such as revenue, net income, and market capitalization, along with upcoming earnings dates. The content also a", "url": "https://www.tradingview.com/symbols/NASDAQ-ATRC/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T09:40:49", "published_display": "26 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure, Inc. Actuals & Estimates (DUS:A5I)", "summary": "This article provides financial actuals and estimates for AtriCure, Inc. (DUS:A5I), including its stock ticker, analyst forecast, historical prices, revenue, net income, and EBITDA. It also notes that the company does not pay dividends and details its next earnings report date.", "url": "https://www.tradingview.com/symbols/DUS-A5I/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-06-26T03:40:43", "published_display": "26 Jun 2026 03:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure stock trades up with limited momentum as technical resistance remains", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOSHBUR1g1bTdsYTdqS3pXZ1M4cmJDSDJiVms0X2l0TmJMX19pM0NzdlRtOVZGcWJDZTJPVUljMEI5RGtTRU1yYUY4a1BscGlUdnc0Y1l5djRDbDVZRmNTVkFkM1g2eGtvSjZGbkUyVVhuOGFSZWhOOFJhMHVQTWQ2WGx5WjVhOVM4T3JqVmRMc0tpOHM?oc=5", "source_name": "Traders Union", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure Inc (ATRC) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for AtriCure Inc (ATRC), detailing its volatility, financial risk, and investment risk. The company has a risk assessment score of 6.67, ranking 52 out of 204 in the Healthcare Equipment & Supplies industry, and a beta of 1.27, indicating h", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atrc/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-24T02:41:17", "published_display": "24 Jun 2026 02:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure (ATRC) Stock Could Be 45.4% Undervalued As Growth Narrative Faces A Cash Flow Test", "summary": "AtriCure (ATRC) stock is currently trading around $28.80, with one narrative suggesting it is 45.4% undervalued with a fair value of $52.78, based on strong growth assumptions from its innovative medical devices. However, a discounted cash flow (DCF) model presents a contrasting ", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-atrc/atricure/news/atricure-atrc-stock-could-be-454-undervalued-as-growth-narra", "source_name": "Simply Wall Street", "published_at": "2026-06-21T18:09:26", "published_display": "21 Jun 2026 18:09", "sentiment": "negative", "sentiment_pct": 28, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure (ATRC) Soars 6.2%: Is Further Upside Left in the Stock?", "summary": "AtriCure (ATRC) shares rose 6.2% after a presentation at the Goldman Sachs Global Healthcare Conference, where management reiterated a goal of $1 billion in revenue by 2030 and highlighted market expansion potential from clinical trials. Despite the surge, the stock holds a Zacks", "url": "https://finance.yahoo.com/markets/stocks/articles/atricure-atrc-soars-6-2-113600767.html", "source_name": "Market source", "published_at": "2026-06-19T11:40:46", "published_display": "19 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 68, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure Inc (ATRC) Financial Health: Profitability & Balance Sheet Analysis", "summary": "AtriCure Inc (ATRC) currently holds a robust financial score of 7.37, ranking 81st in the Healthcare Equipment & Supplies industry. The company reported a significant quarterly revenue increase of 14.26% year-over-year, reaching $141.25 million, and a net profit increase of 101.6", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atrc/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T16:10:38", "published_display": "18 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure Inc (ATRC) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of AtriCure Inc (ATRC), detailing its current price momentum score, support and resistance levels, and indicator readings. It shows that ATRC is trading between a resistance level of $30.29 and a support level of $26.34, suggesting poten", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atrc/technical", "source_name": "TradingKey", "published_at": "2026-06-18T07:44:51", "published_display": "18 Jun 2026 07:44", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure Inc (ATRC) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for AtriCure Inc (ATRC), detailing its current earnings forecast score, average price target, and analyst ratings. Based on 10 analysts, the stock has a \"Buy\" trend with an average target price of $50.00 and an expected revenue of $152.0", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atrc/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T06:38:59", "published_display": "18 Jun 2026 06:38", "sentiment": "positive", "sentiment_pct": 81, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure Inc (ATRC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTFBMZUtaQ3A1YkFFRjVQMUpzZl9BU2RjdUJGdE9pQUpacXg1VVBNQnBzcGk2aS1seXhBb1hpX2RyWWJ5WFZXYWlkd3lJanBheUROdnNGX3JhOVdackJiUVlTOEJQMjQwRWQ4Zl9HZ2t3?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T21:00:31+00:00", "published_display": "17 Jun 2026 21:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure Inc (ATRC) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure and institutional holdings of AtriCure Inc (ATRC). It lists the major shareholders, their proportion of holdings, and categorizes shareholders by type. The report also provides a historical overview of institutional shareholding data", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atrc/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T21:10:11", "published_display": "17 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure (ATRC) Declines 2.8% as Shares Approach Critical Support at $26.58 - Sweep Order Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOYXA5S2Y4a2lsdTVaNDd6Zml3eUFpcEp5TXVRMTJrZnhKOXV3NzdJNE5QVUVqQVFRNFZEZXJoSHlYdDBCWHZNVzZXUjBoR1E3dW54WnY1Yk52WGRqRnA1X3FxY1pUekMyeHQxUGkyUnZrQXlncF9ETEFCSUdNOS1LcUVDQWdHVGJMZTYzRF9yNElMYmJwLWY5V2k5NTdvaXhha090VVZjUnZZLXBYYlN4QklvVXlnVzFzWkE?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Do Options Traders Know Something About AtriCure Stock We Don't?", "summary": "", "url": "https://finance.yahoo.com/markets/options/articles/options-traders-know-something-atricure-134300217.html", "source_name": "Zacks", "published_at": "2026-06-11T13:43:00+00:00", "published_display": "11 Jun 2026 13:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At AtriCure (ATRC) Valuation As BoxX NoAF Trial Acceleration Draws Investor Attention", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNSjNOUFdKWlV0b0M4N21IY0FYaS1yM2dEa2pIYVBuZ2tON3YtbkRMRVBySHNfOERyazBNZGtSMm4teFlBTlpjbWV0VFprTkVZTEQ4ODNOcE1uemNtYVNaU2dPMHVOc0FfcHdXYTJuVTlqdGhnckFVakgyZXRNbk1faWdHQmd6MktoajVTclNQMlpCWkZnYWJtbG1KRzJJT3M?oc=5", "source_name": "Market source", "published_at": "2026-06-06T07:00:00+00:00", "published_display": "06 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure (ATRC) Advances Key Heart Disease Trial 12 Months Ahead of Schedule", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/atricure-atrc-advances-key-heart-214556164.html", "source_name": "Insider Monkey", "published_at": "2026-06-04T21:45:56+00:00", "published_display": "04 Jun 2026 21:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook", "summary": "", "url": "https://finance.yahoo.com/m/b304e545-2f29-370c-8775-b28720e2612f/atricure-conference%3A-new.html", "source_name": "MarketBeat", "published_at": "2026-05-12T19:10:19+00:00", "published_display": "12 May 2026 19:10", "sentiment": "positive", "sentiment_pct": 58, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing AtriCure (ATRC) Valuation After A Prolonged Share Price Decline", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOVHFXRnl3Um1oTjB0Wm9jMWJ6cXV6eDVIRkNTaXhxQ1hyNnZ4YkJPQW1HeTRDOU1zWmJtWXBDOUthdy16RkpSSmNFN3YwYjduWjlJejJvTXVydkxSTlJoMU15X0x6eDFaZWVrOWpPWXNNZ3BMMzF2VXRxYW42NDhXNVlTNld3OHJWWXl5Q0RybUZKdzhJUkVhZFRuVkVmWFUyVDlWRUxraWtleURL?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure (ATRC) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/6159115b-382e-3b04-a527-56479a1fec92/atricure-%28atrc%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-05-06T14:30:28+00:00", "published_display": "06 May 2026 14:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure (ATRC) Reports Break-Even Earnings for Q1", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNSUtQa2lIZFRTRi1mTkxhcXROY0N0d0RlSUF2V1REcjRjcEZRM2NPRzFzeFN1VmRsWVJzX3dHejNKZUVrS0paT3ZxQmh6REx4S0dLZUxUbGNtZlhyWUFDVHNZWXV4T1YtSk92a1ZkeGhMd2c4TVBaM01OWkN6M0NaWFpiaEFEMURIczVpOHl5SElnVW1HN2xwOHBrSGpZRWJhOTlV?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atricure stock hits 52-week low at $27.30 amid market challenges", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQalhmcDF1MnJTVmhpcHlvakxIZG5kZV8tNzRHWC1fMkJTNm5sOG5PQWlYeDA3ekFPZWEzNXlFZ1k1akxZcFBKU2JDYXpsc1g4c19EMmtqSngtNjRjaFk5c0k3OEZUSVZWN0JWb01ZYXpMNlFDN2ZoN2gyRjRZNUk0c3N5RENXUVUwX1JLVnhhdWF1ejk4YUFHMUwxWHY5MXg1TnJQX3B3U3dWZ0U3RjZIeDBBb05xODZyVnc?oc=5", "source_name": "Investing.com", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing AtriCure (ATRC) Valuation After Prolonged Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNU1hDcmR2MkRZYkhnZGV6cy1OMmlnUWo1alhfRFRZWjN2ZmhnRG5na0tyRy04NGo4MVJlbjNFVGV0N2JJZUt3RnEzcWNGVEE2NmpxbEdJRzk1RW5JSWlPSnNVNTdtZUFjYXBPVEFiSzliUEZfbEowZEY2Si1BZ090NkVMS2RIR3NJTkJJQ28tcWliNTVrOS1aaXYyT3p2eXZKTXZGVVVrbWE4NEc0?oc=5", "source_name": "Market source", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure, Inc. ($ATRC) CEO 2025 Pay Revealed", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxOcUFFZ0s1VldIU2FyZ05MZDhFbkJpZEZYdkN3SThTVjkwTzcyR1lPaTBsa1d0T0NLaE90NlNyWTZQYklOMXQ0LTFrYmFzOHhteFRpR2s2enZWRlBKRWxZdFNqdG5teUswRmZUUmVzdFg3dlVxZ21UZzRUelRVcGZaOU50MA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure CSO Sells 5,000 Shares \u2014 A Modest Trim or a Pattern Worth Watching?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxObW5UcTZWOEZSRklwT0M0cWNCNFBGcUJLdUFTbnBkbDRIWVpRRU1fcmlCa1JMU21PTE5LbjhXNWVrVk9VdjdYZFQ0bmJ1c1dvZGotMXpDRWxTanJSa2ZuVFl6eXc2ZDYzSTFJSHdjNVppSTVoUFFYUENnNVFQdDRVbDI0NXhMM3dmMG5PSXkxQ0EwNk9SOTVTWUhrSHppV3NKZWRBQ2swdWVpbGkzLUZUTFhVOFZkd1lHZ0tPUHpzNW0?oc=5", "source_name": "The Motley Fool", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure Inc (ATRC) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE5aY3JsZm1HRE5xNk9xYkNJNFkwWXBkakJSc2duM0JiNDFCejFTRGJGSXBPR3RqZFg2Y1oxTjh4a21admNyTll0MTdzRGpwb25TTGtMc1NkZw?oc=5", "source_name": "Gotrade", "published_at": "2026-02-05T19:34:30+00:00", "published_display": "05 Feb 2026 19:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AtriCure Stock a Buy or Sell After a Director Dumped 10,000 Shares?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPdDAwOUJfbFNNY2RWVmpOUlpDZ2Ywd21FR1BFTF9BN2xpRlZhU05aQ0hwRDdTSWdwRk5GUS1ydDhNMTdjbmwxV3FJMUtBN2gtdUhvSTNfV2VyQVJKWDNZYUpDeUhTZmxaeEYtbzRKNG9EazRCMHRZTDFYX1VCSlBxNXZkVlFDaElEbUpMcHNwTXVqY0ZmbWl5d1JJS1oydFpMZi03RVNwejZDR1ZmdV91UWNPd0IxdktaalE4?oc=5", "source_name": "The Motley Fool", "published_at": "2025-11-29T08:00:00+00:00", "published_display": "29 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Numerous AtriCure Insiders Sold Stock: Not A Positive Omen", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-30T07:00:00+00:00", "published_display": "30 Jul 2025 07:00", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure (NASDAQ:ATRC) Has Debt But No Earnings; Should You Worry?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-08T07:00:00+00:00", "published_display": "08 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unveiling AtriCure (ATRC)'s Value: Is It Really Priced Right? A Comprehensive Guide", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxNQ0xEeWFBaXRmeHBETjNIUi15ZUNjT3R3a25XN0hjNWZhNGpMNF9TcDV1ZWdzaFYtR3JSVmg5UVpWVmhlNzJvSExHM2kwUnVJVUJoYmxGUkZWTDg0VHF0T1JscjVsVncxTGUyQXFINWFlREJZWklWSFJNOW5qTTJESnhtNnBkTXZlaGVBS1FCZTl5OWV1ZjJoRmVoa3BmMEU1YVJndm9Fclg2WUg4ZlpWRFdWU0VyZHNNNzY4SzZ2S1hrRmE4S2x0YV8wX3RoUUhDQ3FLSEYwVmx5enN0cVE?oc=5", "source_name": "GuruFocus", "published_at": "2023-11-28T08:00:00+00:00", "published_display": "28 Nov 2023 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure agrees to buy LARIAT developer SentreHEART -", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQelhiaXJpNWJtSDJVZE1UWExBM0ZyU0hBRlhleXAxSUZoRE55ZnhhYVVBSTZsS0RteFJHX1pkcGV0NG03NlVFRHJBdXlkWGczTS1fYlViVWN0REhkdHJHYnduZTh2YndZNE9ZbTNVZ0laVzJoZlJ6WVQ0Ymo4QS04QmFtemxWeHBTcmc?oc=5", "source_name": "Cardiac Rhythm News", "published_at": "2019-09-16T07:00:00+00:00", "published_display": "16 Sep 2019 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtriCure enters into definitive agreement to acquire SentreHeart", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOMnZ0cEQ5XzJWY1pPc0tkM2VHTDd3YXhpenJ3X0xIc2Y1QnpkOUhUb3FBdWI1UmRjX0lrWDFrZ2hITEZkVE05N2pldm52MG1faU9uYWlIaVFBaUlCSDdfdmF0dWNkYXVMa28yOUx0VHF0WXZJM3JHVDVTc2VqMC1TRFU2amE4U0xWNWowVGJUc2JhVmpTcHZNSUd3NA?oc=5", "source_name": "Cardiac Rhythm News", "published_at": "2019-08-15T07:00:00+00:00", "published_display": "15 Aug 2019 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATRC Stock Price and Chart \u2014 NASDAQ:ATRC", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE4zeVd1SWE3ZU5xaXN3VVlha0IwZzhic3FKOHpQYlhTQmNJcllGMTZGZkJDUW9PVmJmY2hLeFR6Sm5TRGxjb2N4NlVVUzZpM2txQ1YzM0FLNDcxR0JF?oc=5", "source_name": "TradingView", "published_at": "2017-07-21T02:31:46+00:00", "published_display": "21 Jul 2017 02:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 82, "total_relevant": 50, "sentiment_summary": {"positive": 13, "negative": 5, "neutral": 32, "score": 53, "total": 50, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 15.75, "count": 28}, {"event": "earnings", "label": "Earnings", "weight": 6.6, "count": 12}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 13, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 34.28, "latest_week": "2026-07-10", "one_week_move": 7.8, "four_week_move": 19.1, "twelve_week_move": 15.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.954698, "market_dynamics_buy_signal": false, "relative_strength": -13.109596, "fair_value_gap": 3.2, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 45.8454, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+7.8% over one week, +19.1% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 7}, {"label": "TradingKey", "count": 6}, {"label": "TradingView", "count": 5}, {"label": "Stock Titan", "count": 5}, {"label": "Simply Wall Street", "count": 4}, {"label": "Moomoo", "count": 2}, {"label": "Investing.com", "count": 2}, {"label": "The Motley Fool", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 50}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 28}, {"label": "Earnings", "count": 12}, {"label": "Balance sheet", "count": 3}, {"label": "Analyst action", "count": 3}, {"label": "Guidance", "count": 2}, {"label": "Deals and strategy", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "50", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+7.8% over one week, +19.1% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Is AtriCure's (ATRC) Russell 2000 Defensive Debut Quietly Reframing Its Risk\u2011Reward Profile?"}], "updated_at": "2026-07-15T23:33:59.527938+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}